Actively Recruiting
Randomized Study of Stereotactic Ablative Radiation Therapy Combined With Immunotherapy Versus Immunotherapy Alone for Metastatic Unresectable Renal Cell Cancer
Led by NRG Oncology · Updated on 2026-10-23
240
Participants Needed
348
Research Sites
260 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating whether adding stereotactic ablative radiotherapy SABR to the primary tumor along with standard immunotherapy improves outcomes for patients with metastatic, unresected renal cell carcinoma RCC that cannot be surgically removed. This phase II trial compares the combination of SABR plus immunotherapy to immunotherapy alone, focusing on progression-free survival and tumor response. The study also examines safety, response rates, surgery rates, survival, and explores biomarkers and effects on tumor spread. Participants are randomly assigned in a 21 ratio to either receive immunotherapy alone or immunotherapy combined with SABR. Immunotherapy regimens include various combinations of intravenous monoclonal antibodies nivolumab, ipilimumab, pembrolizumab, avelumab and oral antiangiogenic drugs axitinib, cabozantinib, lenvatinib, administered on schedules ranging from every 2 to 6 weeks. Those in the SABR group receive radiation therapy on three separate days over 1 to 3 weeks alongside their immunotherapy. Throughout treatment, patients undergo CT or MRI scans, possible bone scans, and blood sample collections. After treatment, participants are followed every six months for five years, then annually for three more years to monitor outcomes. The study measures nephrectomy and radiographic progression-free survival up to eight years, along with secondary outcomes like response rates, overall survival, treatment-free survival, and adverse events. Regular imaging and laboratory tests track disease status and treatment effects, supporting long-term safety and efficacy assessment.
CONDITIONS
Brief Title
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here